JAK2 and type 1 diabetes mellitus: The goal of this study is to investigate whether the JAK1/JAK2 inhibitor, baricitinib, has activity against the disease process involved in human T1D with the aim of preventing immune-mediated destruction of insulin-producing beta cells.